Trace amine associated receptor 1 modulates behavioral effects of ethanol

Substance Abuse: Research and Treatment

Volumn 7, Issue , 2013, Pages 117-126

  Lynch, Laurie J ^a   Sullivan, Katherine A ^a   Vallender, Eric J ^a   Rowlett, James K ^a   Platt, Donna M ^a   Miller, Gregory M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Addiction; Alcoholism; Dopamine; Reward; Treatment

Indexed keywords

BRAIN MONOAMINE; G PROTEIN COUPLED RECEPTOR; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; GENOTYPE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REINFORCEMENT; RIGHTING REFLEX;

EID: 84878998439     PISSN: 11782218     EISSN: None     Source Type: Journal    
DOI: 10.4137/SART.S12110     Document Type: Article

References (32)

1. Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A. 2001;98(16):8966-71.
2. Lindemann L, Meyer CA, Jeanneau K, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324(3):948-56.
3. Xie Z, Westmoreland SV, Bahn ME, et al. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007;321(1):116-27.
4. Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181-8.
5. Scanlan TS, Suchland KL, Hart ME, et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med. 2004;10(6): 638-42.
6. Panas MW, Xie Z, Panas HN, Hoener MC, Vallender EJ, Miller GM. Trace Amine Associated Receptor 1 Signaling in Activated Lymphocytes. J Neuroimmune Pharmacol. 2012;7(4):866-76.
7. Xie Z, Miller GM. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther. 2009; 330(1):316-25.
8. Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011;116(2):164-76.
9. Xie Z, Miller GM. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. J Pharmacol Exp Ther. 2008;325(2):617-28.
10. Xie Z, Westmoreland SV, Miller GM. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J Pharmacol Exp Ther. 2008;325(2):629-40.
11. Bradaia A, Trube G, Stalder H, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009;106(47):20081-6.
12. Rao A, Simmons D, Sorkin A. Differential subcellular distribution of endosomal compartments and the dopamine transporter in dopaminergic neurons. Mol Cell Neurosci. 2011;46(1):148-58.
13. Miller GM. Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1). J Med Chem. 2012;55(5):1809-14.
14. Kash TL. The role of biogenic amine signaling in the bed nucleus of the stria terminals in alcohol abuse. Alcohol. 2012;46(4):303-8.
15. Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci. 2013;13:127-61.
16. Wolinsky TD, Swanson CJ, Smith KE, et al. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007;6(7):628-39.
17. Vallender EJ, Ruedi-Bettschen D, Miller GM, Platt DM. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug Alcohol Depend. 2010;109(1-3):252-6.
18. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306-14.
19. Achat-Mendes C, Lynch LJ, Sullivan KA, Vallender EJ, Miller GM. Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1. Pharmacol Biochem Behav. 2012;101(2):201-7.
20. Hiroi N, White NM. The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. Brain Res. 1991;552(1):141-52.
21. Urs NM, Daigle TL, Caron MG. A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology. 2011;36(3):551-8.
22. El-Ghundi M, George SR, Drago J, et al. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol. 1998;353(2-3):149-58.
23. Heidbreder CA, Andreoli M, Marcon C, Hutcheson DM, Gardner EL, Ashby CR Jr. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol. 2007;12(1):35-50.
24. Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, et al. The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J. 2006;20(13):2223-33.
25. Rice OV, Patrick J, Schonhar CD, Ning H, Ashby CR Jr. The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice. Synapse. 2012;66(11):975-8.
26. Thanos PK, Katana JM, Ashby CR Jr, et al. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav. 2005;81(1):190-7.
27. Xie Z, Miller GM. Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem Pharmacol. 2009;78(9):1095-104.
28. Revel FG, Meyer CA, Bradaia A, et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012;37(12):2580-92.
29. Revel FG, Moreau JL, Gainetdinov RR, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011;108(20):8485-90.
30. Revel FG, Moreau JL, Gainetdinov RR, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry. 2012;72(11):934-42.
31. Revel FG, Moreau JL, Pouzet B, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18(5): 543-56.
32. Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK, Scanlan TS. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J Med Chem. 2006;49(3):1101-12.